Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL247809 | 0.79 | KDM4E (0.38) | CYP3A4KMT2AMEN1TP53HTT | |
| SCHEMBL28449626 | 0.79 | L3MBTL1 (0.42) | LMNACYP3A4KMT2AMEN1HTT | |
| SCHEMBL8802786 | 0.78 | ALDH1A1 (0.38) | LMNAKMT2AMEN1HTTL3MBTL1 | |
| SCHEMBL16968516 | 0.78 | TACR1 (0.47) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL3342286 | 0.78 | KMT2A (0.35) | TRPM8LMNACYP3A4KMT2AMEN1 | |
| SCHEMBL17220649 | 0.78 | ALDH1A1 (0.40) | LMNAKMT2AMEN1TP53HTT | |
| SCHEMBL7412461 | 0.78 | KDM4E (0.41) | LMNAKMT2AMEN1TP53TSHR | |
| SCHEMBL565646 | 0.77 | TDP1 (0.43) | KMT2AMEN1L3MBTL1ALDH1A1 | |
| SCHEMBL5655590 | 0.77 | CA12 (0.43) | LMNAKMT2AMEN1HTTL3MBTL1 | |
| SCHEMBL1427899 | 0.77 | KMT2A (0.40) | LMNAKMT2AMEN1HTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1353926-B1 | MIKANOLIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USES | SOD CONSEILS RECH APPLIC (FR) | 2006-03-08 | — | — | EP | claimed |
| JP-2004533456-A | — | — | 2004-11-04 | — | — | JP | claimed |
| EP-1438039-A2 | PRODUCT COMPRISING MIKANOLIDE, DIHYDROMIKANOLIDE OR AN ANALOGUE THEREOF COMBINED WITH ANOTHER ANTI-CANCER AGENT FOR THERAPEUTIC USE IN CANCER TREATMENT | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-07-21 | — | — | EP | claimed |
| US-20040138245-A1 | Product comprising mikanolide, dihydromikanolide or an analogue thereof combine with another anti-cancer agent for therapeutic use in cancer treatment | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-07-15 | — | — | US | claimed |
| EP-1353926-A1 | MIKANOLIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USES | Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) | 2003-10-22 | — | — | EP | claimed |
| WO-2002096348-A2 | PRODUCT COMPRISING MIKANOLIDE, DIHYDROMIKANOLIDE OR AN ANALOGUE THEREOF COMBINED WITH ANOTHER ANTI-CANCER AGENT FOR THERAPEUTIC USE IN CANCER TREATMENT | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-12-05 | — | — | WO | claimed |
| WO-2002055523-A1 | MIKANOLIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-07-18 | — | — | WO | claimed |
| EP-1353926-B1 | MIKANOLIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USES | SOD CONSEILS RECH APPLIC (FR) | 2006-03-08 | — | — | EP | disclosed |
| EP-1438039-A2 | PRODUCT COMPRISING MIKANOLIDE, DIHYDROMIKANOLIDE OR AN ANALOGUE THEREOF COMBINED WITH ANOTHER ANTI-CANCER AGENT FOR THERAPEUTIC USE IN CANCER TREATMENT | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-07-21 | — | — | EP | disclosed |
| EP-1353926-A1 | MIKANOLIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USES | Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) | 2003-10-22 | — | — | EP | disclosed |
| WO-2002096348-A2 | PRODUCT COMPRISING MIKANOLIDE, DIHYDROMIKANOLIDE OR AN ANALOGUE THEREOF COMBINED WITH ANOTHER ANTI-CANCER AGENT FOR THERAPEUTIC USE IN CANCER TREATMENT | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-12-05 | — | — | WO | disclosed |
| WO-2002055523-A1 | MIKANOLIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-07-18 | — | — | WO | disclosed |
| EP-0640080-B1 | SUBSTITUTED INDOLES AS ANGIOTENSIN II ANTAGONISTS | SYNTEX INC (US) | 1997-10-22 | — | — | EP | disclosed |
| EP-0640080-A1 | SUBSTITUTED INDOLES AND AZAINDOLES AS ANGIOTENSIN II ANTAGONISTS. | SYNTEX INC (US) | 1995-03-01 | — | — | EP | disclosed |
| US-5380739-A | Angiotensin II antagonists | SYNTEX (U.S.A.) INC. (US) | 1995-01-10 | — | — | US | disclosed |
| WO-1993023391-A1 | SUBSTITUTED INDOLES AND AZAINDOLES AS ANGIOTENSIN II ANTAGONISTS | SYNTEX (U.S.A.) INC. (US) | 1993-11-25 | — | — | WO | disclosed |
| US-5212195-A | Substituted indole antagonists derivatives which are angiotensin II | SYNTEX (U.S.A.) INC. (US) | 1993-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138245-A1 | Product comprising mikanolide, dihydromikanolide or an analogue thereof combine with another anti-cancer agent for therapeutic use in cancer treatment | DTYMK, DGKG, DGKZ | TRPM8 1398/4885LMNA 4782/4885CYP3A4 3179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.